InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million
29 août 2024 18h03 HE
|
InterCure Ltd.
Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA1of NIS 21 million (Approximately 17% of revenues).Both quarters (Q1 and Q2 of 2024) ended with positive...
InterCure Provides an Update Regarding Nir Oz Facility
13 févr. 2024 16h46 HE
|
InterCure Ltd.
NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in...
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain
31 janv. 2024 09h27 HE
|
InterCure Ltd.
NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in...
InterCure Wins Cannolam Arbitration Proceeding
31 oct. 2023 16h39 HE
|
InterCure Ltd.
NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in...
InterCure Provides an Update Regarding the Security Situation in Israel
17 oct. 2023 17h04 HE
|
InterCure Ltd.
NEW YORK, and HERZLIYA, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in...
InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY
31 août 2023 19h45 HE
|
InterCure Ltd.
Achieved record revenues of NIS 209 million ($75 million)1 for the first half of 2023 Annualized revenue run rate of NIS 417 million ($149 million) ...
InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE
10 juil. 2023 17h00 HE
|
InterCure Ltd.
NEW YORK and TORONTO and HERZLIYA, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company"), announced today...
InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger
09 juin 2023 17h18 HE
|
InterCure Ltd.
NEW YORK and TORONTO and HERZLIYA, Israel, June 09, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company"), reports today that,...
InterCure to Participate in the Cowen 3rd Annual European Cannabis Conference
15 mai 2023 17h59 HE
|
InterCure Ltd.
NEW YORK, TORONTO, and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure") today announced that Alexander...
InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY
15 mai 2023 17h45 HE
|
InterCure Ltd.
Achieved record revenues of $40 million for the first quarter Annualized revenue run rate of $159 million Adjusted EBITDA(1) of $6 Million Strong balance sheet with over $45...